CSIMarket
 
Dna Testing Centers Corp  (DNAT)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 22
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Dna Testing Centers Corp
DNA Testing Centers Corp is a company that specializes in providing DNA testing services. They offer a range of genetic testing options, including paternity tests, ancestry tests, and genetic health tests. Their services are often used by individuals seeking to confirm their biological relationships, explore their genetic heritage, or gain insights into their health risks. The company uses advanced laboratory techniques and adheres to strict quality control measures to ensure accurate and reliable results. They also prioritize customer privacy and offer secure and confidential handling of genetic information. DNA Testing Centers Corp aims to provide accessible, affordable, and convenient DNA testing services to individuals and families worldwide.


   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Myriad Genetics Inc

Revolutionizing Cancer Monitoring: Myriad Genetics Inc. Makes Strides in MRD Research and Financial Performance for Q4 2023

r/>Myriad Genetics Inc., a leading molecular diagnostics company, recently announced its participation in an innovative clinical trial that aims to transform the way we monitor minimal residual disease (MRD) across different types of cancer. This collaboration with the National Cancer Center Hospital East in Japan marks a significant milestone in cancer research. By utilizing Myriad's cutting-edge Precise MRD test, researchers aim to evaluate the wide-ranging applicability of MRD monitoring.
Financial Performance for Q4 2023:
In terms of financial performance, Myriad Genetics Inc. observed improvements in several key areas during the fiscal fourth quarter of 2023. The company reported a decreased loss per share, with $-0.36 per share compared to $-0.52 in the previous year. Additionally, the earnings per share (EPS) improved from $-0.75 per share in the preceding reporting season.
The revenue for the fiscal fourth quarter of 2023 increased by 10.574% to $196.60 million from $177.80 million in the same reporting season a year before. Sequentially, the revenue advanced by 2.449% from $191.90 million. Furthermore, the company reported a net shortfall of $-31.200 million, which indicates an improvement compared to the $-42.300 million loss in the same reporting season a year ago.

Celldex Therapeutics Inc

Celldex Therapeutics Inc. Surges Past Competitors with 156% Revenue Growth in 2023

Celldex Therapeutics Inc. has proven its strong revenue growth, demonstrating a remarkable 156.107% increase year on year to reach $4.13 million in the most recent fiscal period. Despite an increased deficit per share at $-0.82, the surge in revenue during the fourth quarter of 2023 has positioned Celldex Therapeutics advantageously within the In Vitro and In Vivo Diagnostic Substances sector. Comparatively, its contemporaries in the same sector only experienced average top-line growth of 14.97% during the same period.
In the preceding reporting period, Celldex Therapeutics Inc. witnessed a significant improvement in its financials as its deficit per share increased from $-0.81 to $-0.82, while revenue doubled by an impressive 172.314% from $1.52 million. These numbers showcase the company's strong growth trajectory and financial stability.

Idexx Laboratories Inc

In Vitro and In Vivo Diagnostic Substances Company Reports Strong Revenue Growth in Q4 20232.

The financial results of Idexx Laboratories Inc for the fourth quarter of 2023 paint a mixed picture of their performance. On one hand, the company saw a significant increase in revenue of 8.762% to $901.16 million compared to the previous year. This growth is a positive sign of the company's ability to generate more income and attract more customers.
Similarly, the increase in EPS by 11.69% to $2.32 per share is also a good indicator of the company's profitability and efficiency in managing costs. These numbers show that Idexx Laboratories Inc is on a solid financial footing and is able to deliver value to its shareholders.

Lantheus Holdings Inc

Lantheus Holdings Inc. Reports Positive Income Growth in Fiscal Period Ending December 31, 20232.

Lantheus Holdings Inc. (LNTH) is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight, and Follow disease in order to deliver better patient outcomes. The company recently reported impressive financial results for its fiscal period ending December 31, 2023. LNTH's net income turned positive, with earnings of $1.45 per share compared to a loss of $1.61 per share the previous year. Although income faded by -22.68% from $1.88 per share in the preceding reporting period, the company?s revenue experienced a significant increase of 34.557% to $354.11 million from $263.17 million in the same period a year before. Sequentially, revenue advanced by 11.023% from $318.95 million.
LNTH's top-line growth in the fourth quarter of 2023 is consistent with its peers in the In Vitro and In Vivo Diagnostic Substances sector, which reported an overall 5.74% revenue increase in the same period. It is worth noting that Lantheus Holdings Inc. achieved net profits of $103.38 million in the fiscal period ending December 31, 2023, a significant improvement compared to a net shortfall of $-119.185 million in the same period the previous year. The company also highlighted its improving profit margins, with the net margin rising to 29.19% and the operating margin edging up to 38.83% in the fiscal period ending December 31, 2023.

Biomerica Inc

Biomerica Inc Shows Improvement in Earnings Despite Revenue Decline

Biomerica Inc, a global provider of advanced medical products, recently reported their financial results for the second quarter of 2024. The company showed a loss of $-0.09 per share, which was an improvement from the loss of $-0.12 per share compared to the same period last year. However, there was a slight increase in shortfall from the previous reporting season, going from $-0.07 per share.
Despite the losses, Biomerica Inc saw a revenue growth of 5.742% to $1.57 million in the second quarter of 2024, up from $1.48 million in the same period last year. However, there was a sequential revenue deterioration of -8.523% from the previous quarter. The company's business surge was short of 11.12% compared to the second quarter of 2023, which was seen across the In Vitro and In Vivo Diagnostic Substances sector.






 

Dna Testing Centers's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com